A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

计划入组 59 人 · 首次发布于 2015 年 3 月 20 日

The RESTORE-SIRIO Randomized Controlled Trial

首次发布于 2015 年 4 月 1 日

Prospective Validation of Liver Cancer Risk Computation (LIRIC) Models

计划入组 6,000,000 人 · 首次发布于 2023 年 11 月 20 日

Liriodenine

CaV2.3 ion channel inhibitor(Lario)

Sirio Pharma Co., Ltd.

China

ASOCIACION DE BENEFICENCIA HOSPITAL SIRIO LIBANES

Argentina

SOCIEDADE BENEFICENTE DE SENHORAS HOSPITAL SIRIO LIBANES

Brazil

Predictive Analytics and AI Are Reshaping Medication Adherence: Moving Beyond Patient Education to Actionable Intervention

Lario Therapeutics Secures $2.4M to Advance Neuronal Calcium Channel Platform for Parkinson's and PTSD